Coronary Artery Disease Market Report 2025

The coronary artery disease market size has grown strongly in recent years. It will grow from $29.15 billion in 2024 to $31.97 billion in 2025 at a compound annual growth rate (CAGR) of 9.7%. The growth in the historic period can be attributed to prevalence of coronary artery disease, growth in minimally invasive surgeries, increase in sedentary lifestyles, aging population and cad prevalence, evolution of pharmacological treatments.

The coronary artery disease market size is expected to see rapid growth in the next few years. It will grow to $48.48 billion in 2029 at a compound annual growth rate (CAGR) of 11%. The growth in the forecast period can be attributed to growing lifestyle factors, focus on telemedicine and remote monitoring, expansion of interventional cardiology procedures, shift towards value-based healthcare models, and development of novel drug therapies. Major trends in the forecast period include the development of gene therapies, integration of artificial intelligence in diagnosis, focus on mental health in CAD care, rise in home-based healthcare services, and adoption of remote cardiac rehabilitation.

The increasing prevalence of coronary artery disease is anticipated to drive the growth of the coronary artery disease market in the coming years. Coronary artery disease (CAD) is a medical condition marked by the narrowing or blockage of the coronary arteries, which supply blood to the heart muscle. The rise in CAD cases can be attributed to dietary changes, stress, lack of exercise, obesity, aging, and other factors. Treatment options for coronary artery disease include medications such as clopidogrel, ticagrelor, warfarin, and heparin, as well as procedures like coronary artery bypass grafting, angioplasty, and stenting. For example, in May 2024, the Centers for Disease Control and Prevention (CDC), a US-based federal agency under the Department of Health and Human Services, reported that coronary heart disease (CHD) was the leading type of heart disease, resulting in 371,506 deaths in 2022. Approximately 5% of adults aged 20 and older (1 in 20) were affected by coronary artery disease (CAD). In 2022, about 1 in 5 deaths from cardiovascular disease (CVD) occurred in adults under 65 years old. Therefore, the rise in the prevalence of coronary artery disease is expected to boost the coronary artery disease market during the forecast period.

The increasing aging population is expected to drive the growth of the coronary artery disease market in the future. An aging population refers to a demographic shift characterized by a growing proportion of elderly individuals within society over time. This aging demographic significantly contributes to the expansion of the coronary artery disease market, as older individuals are more vulnerable to this condition. For example, in October 2022, a report from the World Health Organization (WHO), a Switzerland-based agency focused on international public health, indicated that one in six people is projected to be 60 or older by 2030 worldwide. By 2050, the global population of individuals aged 60 and above is expected to reach 2.1 billion. Therefore, the rising aging population is driving the coronary artery disease market.

Prominent companies within the coronary artery disease market are directing their efforts toward developing cutting-edge technologies, including AI-based blood tests. These tests leverage artificial intelligence (AI) algorithms for the analysis and interpretation of blood-related data. For instance, in February 2023, Cardio Diagnostics Holdings, a US-based company specializing in AI-based integrated genetic-epigenetic engines, introduced PrecisionCHD. This innovative blood test combines genetic and epigenetic analyses to enable early identification of coronary heart disease. With a sensitivity of over 75% for both men and women, PrecisionCHD employs a machine-learning model derived from the analysis of billions of genomic and epigenomic data points, incorporating epigenetic (DNA methylation) and genetic (single nucleotide polymorphism) biomarkers.

Major companies in the coronary artery disease market are concentrating on developing innovative products, such as drug-coated balloon catheters, to drive revenue growth. Drug-coated balloon catheters are medical devices utilized in interventional cardiology to treat narrowed or blocked blood vessels, particularly in cases of coronary artery disease or peripheral artery disease. For example, in March 2024, Boston Scientific Corporation, a US-based medical device company, announced that the US Food and Drug Administration (FDA) had approved the AGENT Drug-Coated Balloon (DCB) for the treatment of coronary in-stent restenosis (ISR) in patients with coronary artery disease. ISR refers to the obstruction or narrowing of a stented vessel due to plaque or scar tissue. The AGENT DCB provides a specialized treatment option for the challenging issue of in-stent restenosis, addressing a significant unmet medical need. It is specifically designed for treating ISR as well as previously untreated small vessel coronary disease. Currently available in Europe, parts of Asia Pacific, and Latin America, the AGENT DCB offers a targeted solution for these complex cardiovascular conditions.

In April 2023, Abbott Laboratories, a prominent US-based medical devices and healthcare company, completed the acquisition of Cardiovascular Systems Inc. for a total consideration of $890 million. This strategic acquisition is designed to enhance Abbott's capabilities in addressing vascular disease by integrating the innovative solutions developed and commercialized by Cardiovascular Systems Inc. The latter, based in the United States, is a medical device company with a focus on creating and bringing to market advanced treatments for peripheral and coronary artery disease. This move is indicative of Abbott's commitment to expanding its portfolio and strengthening its position in the medical devices sector, particularly in the field of cardiovascular health.

Major companies operating in the coronary artery disease market include Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Abbott Laboratories, GlaxoSmithKline plc, Gilead Sciences Inc., Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Aurobindo Pharma Ltd., Hikma Pharmaceuticals plc, Amneal Pharmaceuticals Inc., Chiesi Farmaceutici S.p.A., Lupin Pharmaceuticals Inc., Wockhardt Ltd., Honya Medical Inc., Idorsia Pharmaceuticals Ltd., Cytokinetics Inc., Kowa Pharmaceuticals America Inc., Sinotau Pharmaceutical Group, HRV Global Life Sciences, Barr Pharmaceuticals Inc., AdvanceCor GmbH, Deutsches Zentrum für Herz- Kreislauf-Forschung (DZHK) e.V.

North America was the largest region in the coronary artery disease market in 2024. The regions covered in the coronary artery disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the coronary artery disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Coronary artery disease (CAD) is a medical condition affecting the coronary arteries, responsible for supplying oxygen-rich blood to the heart muscle. The disease occurs when these arteries become narrowed or obstructed due to the accumulation of plaque - a buildup of cholesterol, fat, calcium, and other substances.

Primary treatments for coronary artery disease encompass various approaches such as medication, surgical interventions, additional therapies, and other related strategies. Medications include pharmaceutical substances such as clopidogrel, atorvastatin, metoprolol, lisinopril, losartan, amlodipine, nitroglycerin, among others. Diagnosis involves medical procedures such as electrocardiogram (ECG), echocardiogram, stress tests, cardiac catheterization, heart CT scans, and other diagnostic methods. These medications and diagnostic procedures are made available through diverse distribution channels such as hospital pharmacies, retail pharmacies, online pharmacy platforms, and others. The utilization of these treatments and diagnostic measures extends to hospitals, specialty clinics, and other healthcare facilities.

The coronary artery disease market research report is one of a series of new reports that provides coronary artery disease market statistics, including coronary artery disease industry global market size, regional shares, competitors with a coronary artery disease market share, detailed coronary artery disease market segments, market trends and opportunities, and any further data you may need to thrive in the coronary artery disease industry. This coronary artery disease market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The coronary artery disease market includes revenues earned by entities by providing coronary angioplasty, coronary artery bypass and heart transplant services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.